Vastagbélrák: vizsgálatok itt: Kína
616 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Where
- Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang, Shanghai, Shenyang, Shenzhen, Sichuan, Taiyuan, Tianjin, Wuhan
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06662786 · EU 2024-513852-13-00 - 3. fázisTaking peopleA Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Where
- Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin, Huizhou, Lanzhou, Nanchang, Shanghai, Shenyang, Tianjin, Wuhan
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06750094 · EU 2024-513853-66-00 - No phaseNot yet taking people in KínaFeasibility Study of Huangqi Yangyuan Formula for Capecitabine-Induced Adverse Reactions in Advanced Colorectal Cancer
- Where
- Shijiazhuang
- Életkor
- 18 év to 80 év
- People
- 35
- Run by
- Huanfang Fan
See details and how to joinNCT07913516 - No phaseTaking peoplePre-emptive Endoscopic Vacuum Therapy Reduces the Incidence of Anastomotic Leakage After Colorectal Cancer Surgery
- Where
- Nanchong
- Életkor
- 18 év to 85 év
- People
- 110
- Run by
- Nanchong Central Hospital
See details and how to joinNCT07208786 - 3. fázisNot yet taking people in KínaA Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Where
- Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Hohhot, Jinan, Jining, Jinzhou, Lanzhou, Meizhou, Nanchang, Nanning, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07284849 · EU 2025-523735-19-00 - 1/2. fázisTaking peopleA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00 - 2. fázisTaking peopleIvarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 33
- Run by
- Renmin Hospital of Wuhan University
See details and how to joinNCT07896096 - 2. fázisTaking peopleToripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 46
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07896681 - 2. fázisNot yet taking people in KínaPhase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer
- Where
- Guangdong
- Életkor
- 18 év and over
- People
- 412
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT07895355 - 2/3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Jiangsu, Nanning, Nanyang, Shanghai, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Yangzhou
- Életkor
- 18 év and over
- People
- 990 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221357 · EU 2025-523224-45-00 - No phaseCsak meghívásosReinforced Versus Conventional Anastomosis in Laparoscopic Low Rectal Cancer Resection: A Comparative Study
- Where
- Shanghai
- Életkor
- 18 év to 85 év
- People
- 300
- Run by
- Shanghai 10th People's Hospital
See details and how to joinNCT07346534 - 2. fázisTaking peopleSCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Ruijin Hospital
See details and how to joinNCT07888309 - 2. fázisTaking peopleA Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
- Where
- Beijing, Bengbu, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Shanghai, Wuhan
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Vividion Therapeutics, Inc.
See details and how to joinNCT07811193 · EU 2026-525507-26-00 - 2. fázisTaking peopleBecotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 31
- Run by
- Fudan University
See details and how to joinNCT07884188 - 2. fázisTaking peoplePersonalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1,Chemotherapy and Target Therapy for Metastatic Colorectal Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 116
- Run by
- Fudan University
See details and how to joinNCT06841159 - 3. fázisTaking peopleA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Where
- Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanning, Shenyang, Taiyuan, Ürümqi, Wuhan, Wuxi, Yinchuan, Zhengzhou
- Életkor
- 18 év and over
- People
- 990 worldwide
- Run by
- AbbVie
See details and how to joinNCT07525206 · EU 2025-521712-19-00 - 2. fázisNot yet taking people in KínaFOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
- Where
- Guangzhou, Shanghai
- Életkor
- 18 év and over
- People
- 229
- Run by
- Sun Yat-sen University
See details and how to joinNCT07621497 - 1. fázisTaking peopleEMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer
- Where
- Beijing, Guangzhou
- Életkor
- 18 év to 74 év
- People
- 120
- Run by
- Shanghai EpimAb Biotherapeutics Co., Ltd.
See details and how to joinNCT07649655 - 1/2. fázisTaking peopleA Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
- Where
- Chengdu, Guangzhou, Guilin, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Tianjin
- Életkor
- 18 év to 75 év
- People
- 369
- Run by
- Nanjing Leads Biolabs Co.,Ltd
See details and how to joinNCT07791758 - 3. fázisNot yet taking people in KínaChemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 480
- Run by
- Fudan University
See details and how to joinNCT07877597 - No phaseTaking peopleMesogastrium Metastasis in Colon Cancer
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Jichao Qin
See details and how to joinNCT04980287 - 3. fázisTaking peopleNeoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 210
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT06850090 - 2. fázisTaking peopleLow-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 50
- Run by
- Sun Yat-sen University
See details and how to joinNCT07448142 - No phaseTaking peopleConcordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer
- Where
- Jinan
- Életkor
- 18 év and over
- People
- 180
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT07595107 - 2. fázisNot yet taking people in KínaA Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07814417 · EU 2026-526138-23-00